Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Azithromycin as add-on therapy in patients failing medical and surgical treatment for chronic rhinosinusitis: a double-blind, randomized, placebo-controlled trial
EF 2014-15
Résumé
Title
Azithromycin as add-on therapy in patients failing medical and surgical treatment for chronic rhinosinusitis: a double-blind, randomized, placebo-controlled trial
Justification
Chronic rhinosinusitis (CRS) is one of the most common inflammatory diseases with an incidence and prevalence of 10%. Unfortunately, more than 30% of patients do not respond to standard medical and surgical treatment, continuously increasing the symptomatologic and socio-economic burden of this disease.
Hypothesis
We believe that the addition of azithromycin (AZI) to the treatment regimen of patients with refractory CRS failing conventional medico-surgical treatment will be beneficial in a symptomatologic and endoscopic level.
Primary Objective
Evaluate whether Azithromycin 250 mg PO three times
weekly is effective in controlling signs and symptoms of CRS in
high-risk patients unresponsive to standard management after endoscopic sinus surgery and
budesonide irrigations (BUDI).
Study design
Patients meeting inclusion and exclusion criteria operated for CRS will receive BUDI postoperatively. Patients with signs and symptoms of disease recurrence despite BUDI will enter the double-blind randomized placebo-controlled trial.
Long-term significance
Identifying a more personalized approach to the disease can lead to significant symptom alleviation, decreased need for additional medical and surgical interventions and an important socioeconomic gain. Furthermore, properly identifying and characterizing this population, as well as the immunomodulatory aspects of azithromycin in CRS can open future therapeutic avenues not only in rhinology but in respiratory diseases as a whole.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
331473
Name
Maniakas Anastasios
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Azithromycin as add-on therapy in patients failing medical and surgical treatment for chronic rhinosinusitis: a double-blind, randomized, placebo-controlled trial
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Azithromycin; Chronic Rhinosinusitis; Clinical Trial; Corticosteroid Therapy; Endoscopic Sinus Surgery; Macrolide; Personalized Medicine
Abstract
Title
Azithromycin as add-on therapy in patients failing medical and surgical treatment for chronic rhinosinusitis: a double-blind, randomized, placebo-controlled trial
Justification
Chronic rhinosinusitis (CRS) is one of the most common inflammatory diseases with an incidence and prevalence of 10%. Unfortunately, more than 30% of patients do not respond to standard medical and surgical treatment, continuously increasing the symptomatologic and socio-economic burden of this disease.
Hypothesis
We believe that the addition of azithromycin (AZI) to the treatment regimen of patients with refractory CRS failing conventional medico-surgical treatment will be beneficial in a symptomatologic and endoscopic level.
Primary Objective
Evaluate whether Azithromycin 250 mg PO three times
weekly is effective in controlling signs and symptoms of CRS in
high-risk patients unresponsive to standard management after endoscopic sinus surgery and
budesonide irrigations (BUDI).
Study design
Patients meeting inclusion and exclusion criteria operated for CRS will receive BUDI postoperatively. Patients with signs and symptoms of disease recurrence despite BUDI will enter the double-blind randomized placebo-controlled trial.
Long-term significance
Identifying a more personalized approach to the disease can lead to significant symptom alleviation, decreased need for additional medical and surgical interventions and an important socioeconomic gain. Furthermore, properly identifying and characterizing this population, as well as the immunomodulatory aspects of azithromycin in CRS can open future therapeutic avenues not only in rhinology but in respiratory diseases as a whole.
Competitiondate
201412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Maniakas, Anastasios
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~